抗體藥物複合體

 

產品分類：*CDMO

廠商名稱：台耀化學股份有限公司

攤位號碼：M314

 

產品特色

 

One-stop service
Formosa Labs provides a one-stop solution to client’s ADC projects. One-stop service means adaptive planning, cost management, and time efficiency for our client. In terms of ADC development, Formosa Labs supports every aspect from the design and creation of ADC, linker-payload chemistry, to the GMP manufacturing and filling of injectable drug products.

ADC Services in Formosa Labs:
Antibody development and manufacture
Peptide and polymer drug conjugation
Linker-payload design, synthesis, and manufacturing.
Bio-conjugation and purification (TFF, chromatography)
Cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture
Regulatory support

Experiences in ADC
10 years experience in ADC development
15 years experience of high potency API
18 active projects under clinical development

With more than 10 years experience of high potency API and ADC, Formosa Labs starts biosimilar project of Kadcyla in 2013. Per CDMO business, we have supplied the clinical trial materials to the US, EU, and Asia regions. Formosa Labs expands the capacity of ADC production and reach 50 kg annual capacity for our customer in the next decade.


ADC and Linker-Payload Platform
Our high potency/bio-conjugation labs in Formosa Labs support the ADC research samples from candidate design to product delivery.
The proprietary linker-payload platform of Formosa Laboratories aims to provide high DAR (drug-antibody ratio) ADC product. With this platform, we can delivery ADC candidate in 1 month.
To the aspect of handling the complexity of in ADC and high potency API, Formosa Labs has the ability to synthesize cytolysine in a 40-step synthesis process. With our in depth chemistry experience, we walk along with with our customer for their ADC from beginning.

 

相關產品

 

• 

  無菌針劑藥品開發及製造服務

• 

  原料藥

• 

  客製化服務

 

 

 

回列表